Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Eli Lilly and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational drug evacetrapib, due to insufficient efficacy for the treatment of high-risk atherosclerotic cardiovascular disease (ASCVD).
The recommendation from the independent data monitoring committee was based on information from periodic data reviews, which suggested a low probability for the study to achieve its primary endpoint based on results to date. The study termination is not due to any safety findings. Results of ACCELERATE will be presented in future scientific forums after further analysis.
RELATED: CAC Absence Reclassifies Half of Those Not Eligible for Statins
The ACCELERATE study was designed to evaluate the efficacy and safety of evacetrapib in patients with high-risk ASCVD. The primary outcome measure was designed to be time to first occurrence of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. Evacetrapib is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), with effects on high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and cholesterol efflux.
For more information call (800) 545-5979 or visit Lilly.com.
